146 related articles for article (PubMed ID: 30319127)
21. Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.
Jarvis C; Nelius T; Martinez-Marin D; Sennoune SR; Filleur S
Prostate; 2018 Sep; 78(12):905-914. PubMed ID: 29749077
[TBL] [Abstract][Full Text] [Related]
22. Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer.
Oudard S; Kramer G; Caffo O; Creppy L; Loriot Y; Hansen S; Holmberg M; Rolland F; Machiels JP; Krainer M
BJU Int; 2015 May; 115(5):744-52. PubMed ID: 24947139
[TBL] [Abstract][Full Text] [Related]
23. Aged patients with metastatic castration resistant prostate cancer: Should we treat with chemotherapy?
Climent MÁ; Torregrosa MD; Vázquez S; Gironés R; Arranz JA
Cancer Treat Rev; 2017 Apr; 55():173-180. PubMed ID: 28411479
[TBL] [Abstract][Full Text] [Related]
24. Continuous versus intermittent docetaxel for metastatic castration resistant prostate cancer.
Gyawali B; Koomulli-Parambil S; Iddawela M
Crit Rev Oncol Hematol; 2016 Jun; 102():118-24. PubMed ID: 27157868
[TBL] [Abstract][Full Text] [Related]
25. Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view.
Bracarda S; Sisani M; Marrocolo F; Hamzaj A; Del Buono S; Altavilla A
Expert Rev Anticancer Ther; 2014 Nov; 14(11):1283-94. PubMed ID: 25353258
[TBL] [Abstract][Full Text] [Related]
26. Clinical concepts for cabazitaxel in the management of metastatic castration-resistant prostate cancer.
Al-Mansouri L; Gurney H
Asia Pac J Clin Oncol; 2019 Dec; 15(6):288-295. PubMed ID: 31313526
[TBL] [Abstract][Full Text] [Related]
27. [Role of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) treatment: still standard or exception?].
Thomas C
Urologie; 2023 Dec; 62(12):1281-1288. PubMed ID: 37904040
[TBL] [Abstract][Full Text] [Related]
28. Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer: A Case Report and Review of Literature.
Di Lorenzo G; Pagliuca M; Perillo T; Benincasa A; Bosso D; De Placido S; Buonerba C
Medicine (Baltimore); 2016 Apr; 95(14):e2754. PubMed ID: 27057826
[TBL] [Abstract][Full Text] [Related]
29. Significance of De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Significant Prognostic But Not Predictive Biomarker in Japanese Patients with Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel.
Miyake H; Matsushita Y; Watanabe H; Tamura K; Suzuki T; Motoyama D; Ito T; Sugiyama T; Otsuka A
Anticancer Res; 2018 Jul; 38(7):4179-4185. PubMed ID: 29970547
[TBL] [Abstract][Full Text] [Related]
30. Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer.
Miyake H; Sakai I; Terakawa T; Harada K; Fujisawa M
Urol Oncol; 2013 Aug; 31(6):733-8. PubMed ID: 21782481
[TBL] [Abstract][Full Text] [Related]
31. Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC).
Sonpavde G; Wang CG; Galsky MD; Oh WK; Armstrong AJ
BJU Int; 2015 Jul; 116(1):17-29. PubMed ID: 25046451
[TBL] [Abstract][Full Text] [Related]
32. [Chinese experts consensus on the treatment of metastatic prostate cancer 2018 edition].
Chinese Anticancer Association Genitourinary Oncology Committee
Zhonghua Wai Ke Za Zhi; 2018 Sep; 56(9):646-652. PubMed ID: 30157568
[TBL] [Abstract][Full Text] [Related]
33. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer.
Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
Anticancer Res; 2014 Nov; 34(11):6705-10. PubMed ID: 25368278
[TBL] [Abstract][Full Text] [Related]
34. Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluation.
Bracarda S; Caserta C; Galli L; Carlini P; Pastina I; Sisani M; Scali S; Hamzaj A; Derosa L; Felici A; Rossi M; Altavilla A; Chioni A; De Angelis V
Future Oncol; 2015 Nov; 11(22):3083-90. PubMed ID: 26437324
[TBL] [Abstract][Full Text] [Related]
35. Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel.
Sonpavde G; Pond GR; Templeton AJ; Fandi A; Tombal B; Rosenthal M; Armstrong AJ; Petrylak DP
Eur Urol; 2016 Jun; 69(6):980-3. PubMed ID: 26497922
[TBL] [Abstract][Full Text] [Related]
36. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.
Azad AA; Leibowitz-Amit R; Eigl BJ; Lester R; Wells JC; Murray RN; Kollmannsberger C; Heng DY; Joshua AM; Chi KN
Prostate; 2014 Nov; 74(15):1544-50. PubMed ID: 25175831
[TBL] [Abstract][Full Text] [Related]
37. Clinical Impact of the Number of Treatment Cycles in First-Line Docetaxel for Patients With Metastatic Castration-Resistant Prostate Cancer.
Kongsted P; Svane IM; Lindberg H; Sengeløv L
Clin Genitourin Cancer; 2017 Apr; 15(2):e281-e287. PubMed ID: 27692811
[TBL] [Abstract][Full Text] [Related]
38. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancer.
Dreicer R
Clin Adv Hematol Oncol; 2015 May; 13(5):293-5. PubMed ID: 26352772
[No Abstract] [Full Text] [Related]
39. Management of Castration-Resistant, Taxane-Resistant Prostate Cancer.
Beer TM
Oncology (Williston Park); 2017 Aug; 31(8):633-6. PubMed ID: 28812304
[TBL] [Abstract][Full Text] [Related]
40. The oncological outcomes and risk stratification in docetaxel chemotherapy for castration-resistant prostate cancer.
Shiota M; Yokomizo A; Adachi T; Koga H; Yamaguchi A; Imada K; Takeuchi A; Kiyoshima K; Inokuchi J; Tatsugami K; Naito S
Jpn J Clin Oncol; 2014 Sep; 44(9):860-7. PubMed ID: 24951829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]